July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug ...

By Nqobile Dludla JOHANNESBURG, July 17 (Reuters) - Novo Nordisk will launch a more affordable authorised copy of its Ozempic ...

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

Viking's latest program seeks to push the envelope in weight loss efficacy.

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising ...

Novo Nordisk is finally getting one up on its biggest rival.

Vivani says its implant delivers medication steadily over long periods of time.

The interim analysis included 426 participants aged one year and above.

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.

The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites ...

Insurance coverage just changed for as many as 56 million Americans when it comes to the popular GLP-1 medications used to ...